Every material Form 8-K Eastman Chemical filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Eastman Chemical reported third-quarter 2025 sales of $2.2 billion, down 11% from $2.46 billion a year earlier, and GAAP diluted EPS of $0.40 versus $1.53. The company attributed the decline mainly to lower sales volume, weak consumer demand, and customers reducing tariff-related inventory. It projects full-year 2025 adjusted EPS of $5.40 to $5.65 and operating cash flow approaching $1 billion, which shareholders will weigh against the sharp year-over-year drop in earnings.
Q3 2025 sales were $2,202 million versus $2,464 million in Q3 2024, down 11%; adjusted EBIT was $210 million versus $366 million.
Q3 2025 adjusted diluted EPS was $1.14 versus $2.26 a year earlier; GAAP diluted EPS was $0.40 versus $1.53.
Operating cash flow was $402 million, compared with $396 million in Q3 2024, helped by $204 million of inventory reduction.
Full-year 2025 adjusted diluted EPS is projected at $5.40 to $5.65, and the company expects to reduce costs by more than $75 million net of inflation in 2025.
Chris M. Killian, Senior Vice President and Chief Technology and Sustainability Officer, plans to retire effective December 31, 2025, citing family and health considerations. Stephen G. Crawford, a former executive, is returning to lead technology projects from November 3, 2025, and will take over Killian's role on January 1, 2026, to support a smooth transition.
Killian retires effective December 31, 2025, citing family and health considerations
Crawford returns as Executive Vice President - Technology Projects effective November 3, 2025
Crawford becomes Executive Vice President - Chief Technology Officer and Chief Sustainability Officer on January 1, 2026
Crawford's compensation includes a $705,000 base salary, an $800,000 sign-on bonus, and a $2,200,000 restricted stock unit grant on or about January 2, 2026
Eastman Chemical reported second-quarter 2025 sales of $2.29 billion, down 3% from a year earlier, and adjusted earnings per diluted share of $1.60 versus $2.15. Lower volumes in Fibers, Chemical Intermediates and Advanced Materials drove the decline, and the company projected third-quarter adjusted EPS of about $1.25 and full-year operating cash flow of about $1 billion, with inventory reduction expected to weigh on earnings in the second half.
Q2 2025 sales $2,287 million vs. $2,363 million in Q2 2024; GAAP diluted EPS $1.20 vs. $1.94
Adjusted EBIT $275 million vs. $353 million; operating cash flow $233 million vs. $367 million
Third-quarter 2025 adjusted EPS projected at about $1.25; full-year operating cash flow expected at about $1 billion
Plans to cut inventory by more than $200 million, with a $75 million to $100 million earnings headwind in the back half of 2025
Eastman Chemical's Board appointed Damon Audia as a director on June 27, 2025, to serve until the 2026 Annual Meeting of Stockholders. He joins the Audit, Finance, and Environmental, Safety and Sustainability committees. For shareholders, this is a board composition change that adds a director with a finance background; the filing reports no financial results or guidance.
Damon Audia appointed director on June 27, 2025, term through the 2026 Annual Meeting of Stockholders
Audia named to Audit, Finance, and Environmental, Safety and Sustainability committees
Audia is Senior Vice President and Chief Financial Officer at AGCO Corporation, which the release describes as an $11.7 billion company
Eastman Chemical decided on May 1, 2025 to eliminate the executive vice president position held by Steve Crawford, effective June 2, 2025, after he finished leading startup of the Kingsport Methanolysis facility. The company agreed to pay him 52 weeks of base salary plus up to four months of company-paid healthcare coverage, and his duties will move to other executives.
Position eliminated effective June 2, 2025, as part of ongoing succession planning
Severance of 52 weeks' base salary for 41 years of service
Up to four months of continued healthcare coverage paid by the company
Operational responsibilities transferred to other Eastman executives
Eastman reported first-quarter 2025 sales of $2.29 billion, down 1% from a year earlier, while adjusted earnings per share rose 19% to $1.91 and GAAP diluted EPS rose to $1.57 from $1.39. Cash used in operations widened to $167 million, and the company moved to quarterly adjusted EPS guidance, forecasting second-quarter adjusted EPS of $1.70 to $1.90 amid tariff uncertainty, while cutting its capital expenditure target to around $550 million.
Adjusted EPS of $1.91 versus $1.61 a year earlier; GAAP diluted EPS of $1.57 versus $1.39
Sales revenue of $2.29 billion versus $2.31 billion, with Fibers down 13 percent
Net cash used in operating activities of $167 million versus $16 million, driven by inventory build ahead of a planned second-quarter shutdown
Second-quarter 2025 adjusted EPS guidance of $1.70 to $1.90; cost reduction target raised to approximately $75 million and capital expenditures reduced to around $550 million
Eastman Chemical entered a severance agreement with Brad A. Lich dated March 10, 2025, setting out benefits if he is terminated without Cause or resigns for good reason after March 1, 2027. The filing describes a $2 million cash severance payment plus up to four months of company-paid healthcare, and it does not say whether Lich holds a new or changed role.
Agreement with Brad A. Lich dated March 10, 2025
Qualifying triggers: termination without Cause, or good-reason resignation after March 1, 2027
Cash severance of $2 million plus amounts under existing company plans, and up to four months of paid healthcare coverage
Full agreement to be filed with the Form 10-Q for first quarter 2025
Eastman Chemical issued $250 million of 5.000% notes due August 1, 2029, in a public offering, adding to $500 million of the same notes issued in August 2024. The company expects net proceeds of about $246.2 million for general corporate purposes, including working capital, capital expenditures and debt repayment.
Notes: $250 million principal, 5.000% coupon, maturing August 1, 2029, issued February 21, 2025
Expected net proceeds of approximately $246.2 million after underwriting discounts and offering expenses
Underwriting Agreement dated February 18, 2025, with BofA Securities and J.P. Morgan Securities as representatives
Notes form a single series with the $500 million of 5.000% notes issued August 1, 2024
Eastman Chemical reported fourth-quarter and full-year 2024 results, with sales and per-share earnings both higher than a year earlier. The company also projected 2025 EPS of $8.00-$8.75 and cash from operations of about $1.3 billion.
Q4 2024 sales were $2,245 million, up 2% from $2,207 million; GAAP diluted EPS was $2.82 versus $2.61, and adjusted EPS was $1.87 versus $1.31.
Full-year 2024 sales were $9,382 million, up from $9,210 million; GAAP diluted EPS was $7.67 versus $7.49, and adjusted EPS was $7.89 versus $6.40.
Q4 2024 GAAP earnings before interest and taxes fell to $349 million from $477 million, which included a 2023 gain on the Texas City sale.
For 2025, the company expects EPS of $8.00-$8.75 and cash from operations of about $1.3 billion.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Eastman Chemical filing is on SEC EDGAR ↗. 8-K briefs of other companies →